


- Oncology

# Unlock Real-World Oncology Insights with Arcturis Data

We partner with leading UK health systems to transform real-world experiences of cancer patients into high-quality, research-ready datasets and enable their secure use to enhance patient care, improve outcomes, and drive progress in cancer research.

Built in collaboration with leading NHS Trusts and clinicians, our Real World Data Network unlocks a level of depth, precision, and clinical context unmatched in traditional UK real-world data (RWD) sources - enabling deeper insight into complex oncology pathways and more robust evidence generation.



## Driving Smarter, Faster Decisions in Cancer Research

Cancer continues to place a significant burden on patients and healthcare systems, with over 385,000 new cases diagnosed in the UK each year and the NHS spending more than £5 billion annually on cancer care.

As precision medicine reshapes oncology, there is an increasing need for robust real-world evidence (RWE) to complement clinical trials and support faster, better-informed decisions across the drug development lifecycle.

## Our Oncology Data Services

We partner with life science companies to shape fit-for-purpose RWD and RWE solutions that support oncology portfolios across the development lifecycle.

We curate high-quality datasets via our RWD Network of leading hospital systems in the UK. These datasets are unparalleled in the capture of detailed cancer patient journeys, from diagnosis through to treatment and outcomes, enabling the generation of trusted, regulatory-grade RWE to support:

- Drug discovery and clinical development
- Regulatory approvals and Health Technology Assessment (HTA) submissions
- Deep understanding of patient populations and treatment pathways
- External control arms for rare or hard-to-recruit cancers



## What Sets Arcturis Apart?

### Comprehensive, real-time patient-level data

Arcturis provides full secondary care visibility from diagnoses, medications, labs, imaging and pathology reports, as well as multidisciplinary team notes ensuring accurate identification of hard-to-surface patient subgroups, staging and lines of therapy.

### Clinically grounded and methodologically rigorous

Developed in partnership with NHS clinicians, our datasets are not only scientifically sound but also clinically interpretable and aligned with real-world UK practice. This makes our evidence highly relevant for HTA submissions, market access strategies, and comparative effectiveness studies.

### Addressing key RWD limitations

Arcturis data overcomes the challenges seen in previous NICE technology appraisals for oncology such as outdated comparators, inconsistent endpoints, and limited data linkage delivering the robust, current evidence needed to inform decision-making.

## Oncology Case Studies

### Multiple Myeloma

- A cohort of 7,162 patients diagnosed with Multiple Myeloma identified 200 patients for an ECA cohort to drive insights for a single-arm trial
- Pivotal evidence for NICE submission and peer reviewed publication

### Ovarian Cancer

- A cohort of 9,363 patients diagnosed with Ovarian Cancer
- Comprehensive and unrestricted capture of Systematic Anti-Cancer Therapies
- Analysis of unstructured free-text of radiology reports to estimate disease response

### Endometrial Cancer

- A cohort of 8,484 patients diagnosed with Endometrial Cancer
- Extraction of Mismatched Repair Status (MMR) from free-text pathology reports
- Abstract at BGCS and publication in Oncology and Therapy

## More information

Comparison of Outcomes with Elranatamab and Real World Treatments in the UK for Triple Class Exposed Relapsed and Refractory Multiple Myeloma



SCAN ME

A Real-World Retrospective Observational Study of Patients with Advanced/ Recurrent Endometrial Cancer Across England



SCAN ME